Phase_I-II_study_of_advanced_head_and_neck_squamous_cell_carcinoma_patients_treated_with_recombinant_human_interferon_gamma._The_association_of_immunodeficiency_with_head_and_neck_squamous_cell_carcinoma_has_generated_the_concept_of_supplying_immunologically_active_agents_as_a_means_of_treating_these_cancers._One_of_the_most_active_immunologic_messengers_is_interferon_gamma,_which_has_been_observed_in_our_laboratories_to_also_have_a_direct_cytotoxic_effect_on_cultures_of_squamous_cell_carcinoma_derived_from_the_head_and_neck._To_test_the_feasibility_of_treating_patients_with_advanced_but_resectable_head_and_neck_cancer_with_this_agent,_we_designed_a_phase_I-II_trial_of_recombinant_human_interferon_gamma_using_a_24-hour_infusion_repeated_weekly_for_four_times._In_this_study,_both_tumor_and_immunologic_parameters_were_studied_before_and_after_treatment._Eight_patients_were_entered_into_the_study_with_the_highest_recombinant_human_interferon_gamma_dose_attempted_being_0.25_mg/m2_per_24_hours._Minimal_side_effects_were_observed._Three_patients_had_clinically_measurable_responses,_four_had_stabilization_of_disease,_and_one_had_progression_while_receiving_treatment._Histopathologic_results_of_treatment_were_similar_to_in_vitro_observations._Necrosis,_as_well_as_differentiation_of_tumor_cells,_was_observed._In_some_tumors_there_was_a_marked_decrease_in_cellularity_without_a_change_in_tumor_volume_due_to_increased_extracellular_keratin_deposition._Our_study_indicates_that_evaluation_of_adoptive_immunotherapy_trials_in_head_and_neck_cancer_needs_to_include_parameters_other_than_simple_tumor_regression_as_an_end_point,_otherwise_therapeutically_important_lymphokine-induced_changes_may_be_missed._Further_evaluation_of_recombinant_human_interferon_gamma_and_agents_that_induce_human_interferon_gamma_are_warranted.